RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Regulatory Update

Regulatory Update

Posted 01 May 2011 | By Michael Matthews 

The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have launched a voluntary pilot program that will allow parallel evaluation of relevant development and manufacturing data components, known as Quality by Design (QbD), of new drug marketing applications that are submitted to both agencies. QbD in pharmaceuticals involves designing and developing formulations and manufacturing processes to help ensure product manufacturing quality.


© 2022 Regulatory Affairs Professionals Society.